Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant.
Innate immune responses to vaccine adjuvants based on lipopolysaccharide (LPS), a component of gram-negative bacterial cell walls, are driven by Toll-like receptor (TLR) 4 and adaptor proteins including MyD88 and TRIF, leading to the production of inflammatory cytokines, type I interferons, and chem...
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2011-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3027669?pdf=render |
id |
doaj-beb6c4c5d8824c4a9eada22324c31245 |
---|---|
record_format |
Article |
spelling |
doaj-beb6c4c5d8824c4a9eada22324c312452020-11-24T20:50:02ZengPublic Library of Science (PLoS)PLoS ONE1932-62032011-01-0161e1633310.1371/journal.pone.0016333Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant.Rhea N ColerSylvie BertholetMagdalini MoutaftsiJeff A GuderianHillarie Plessner WindishSusan L BaldwinElsa M LaughlinMalcolm S DuthieChristopher B FoxDarrick CarterMartin FriedeThomas S VedvickSteven G ReedInnate immune responses to vaccine adjuvants based on lipopolysaccharide (LPS), a component of gram-negative bacterial cell walls, are driven by Toll-like receptor (TLR) 4 and adaptor proteins including MyD88 and TRIF, leading to the production of inflammatory cytokines, type I interferons, and chemokines. We report here on the characterization of a synthetic hexaacylated lipid A derivative, denoted as glucopyranosyl lipid adjuvant (GLA). We assessed the effects of GLA on murine and human dendritic cells (DC) by combining microarray, mRNA and protein multiplex assays and flow cytometry analyses. We demonstrate that GLA has multifunctional immunomodulatory activity similar to naturally-derived monophosphory lipid A (MPL) on murine DC, including the production of inflammatory cytokines, chemokines, DC maturation and antigen-presenting functions. In contrast, hexaacylated GLA was overall more potent on a molar basis than heterogeneous MPL when tested on human DC and peripheral blood mononuclear cells (PBMC). When administered in vivo, GLA enhanced the immunogenicity of co-administered recombinant antigens, producing strong cell-mediated immunity and a qualitative T(H)1 response. We conclude that the GLA adjuvant stimulates and directs innate and adaptive immune responses by inducing DC maturation and the concomitant release of pro-inflammatory cytokines and chemokines associated with immune cell trafficking, activities which have important implications for the development of future vaccine adjuvants.http://europepmc.org/articles/PMC3027669?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Rhea N Coler Sylvie Bertholet Magdalini Moutaftsi Jeff A Guderian Hillarie Plessner Windish Susan L Baldwin Elsa M Laughlin Malcolm S Duthie Christopher B Fox Darrick Carter Martin Friede Thomas S Vedvick Steven G Reed |
spellingShingle |
Rhea N Coler Sylvie Bertholet Magdalini Moutaftsi Jeff A Guderian Hillarie Plessner Windish Susan L Baldwin Elsa M Laughlin Malcolm S Duthie Christopher B Fox Darrick Carter Martin Friede Thomas S Vedvick Steven G Reed Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS ONE |
author_facet |
Rhea N Coler Sylvie Bertholet Magdalini Moutaftsi Jeff A Guderian Hillarie Plessner Windish Susan L Baldwin Elsa M Laughlin Malcolm S Duthie Christopher B Fox Darrick Carter Martin Friede Thomas S Vedvick Steven G Reed |
author_sort |
Rhea N Coler |
title |
Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. |
title_short |
Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. |
title_full |
Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. |
title_fullStr |
Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. |
title_full_unstemmed |
Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. |
title_sort |
development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2011-01-01 |
description |
Innate immune responses to vaccine adjuvants based on lipopolysaccharide (LPS), a component of gram-negative bacterial cell walls, are driven by Toll-like receptor (TLR) 4 and adaptor proteins including MyD88 and TRIF, leading to the production of inflammatory cytokines, type I interferons, and chemokines. We report here on the characterization of a synthetic hexaacylated lipid A derivative, denoted as glucopyranosyl lipid adjuvant (GLA). We assessed the effects of GLA on murine and human dendritic cells (DC) by combining microarray, mRNA and protein multiplex assays and flow cytometry analyses. We demonstrate that GLA has multifunctional immunomodulatory activity similar to naturally-derived monophosphory lipid A (MPL) on murine DC, including the production of inflammatory cytokines, chemokines, DC maturation and antigen-presenting functions. In contrast, hexaacylated GLA was overall more potent on a molar basis than heterogeneous MPL when tested on human DC and peripheral blood mononuclear cells (PBMC). When administered in vivo, GLA enhanced the immunogenicity of co-administered recombinant antigens, producing strong cell-mediated immunity and a qualitative T(H)1 response. We conclude that the GLA adjuvant stimulates and directs innate and adaptive immune responses by inducing DC maturation and the concomitant release of pro-inflammatory cytokines and chemokines associated with immune cell trafficking, activities which have important implications for the development of future vaccine adjuvants. |
url |
http://europepmc.org/articles/PMC3027669?pdf=render |
work_keys_str_mv |
AT rheancoler developmentandcharacterizationofsyntheticglucopyranosyllipidadjuvantsystemasavaccineadjuvant AT sylviebertholet developmentandcharacterizationofsyntheticglucopyranosyllipidadjuvantsystemasavaccineadjuvant AT magdalinimoutaftsi developmentandcharacterizationofsyntheticglucopyranosyllipidadjuvantsystemasavaccineadjuvant AT jeffaguderian developmentandcharacterizationofsyntheticglucopyranosyllipidadjuvantsystemasavaccineadjuvant AT hillarieplessnerwindish developmentandcharacterizationofsyntheticglucopyranosyllipidadjuvantsystemasavaccineadjuvant AT susanlbaldwin developmentandcharacterizationofsyntheticglucopyranosyllipidadjuvantsystemasavaccineadjuvant AT elsamlaughlin developmentandcharacterizationofsyntheticglucopyranosyllipidadjuvantsystemasavaccineadjuvant AT malcolmsduthie developmentandcharacterizationofsyntheticglucopyranosyllipidadjuvantsystemasavaccineadjuvant AT christopherbfox developmentandcharacterizationofsyntheticglucopyranosyllipidadjuvantsystemasavaccineadjuvant AT darrickcarter developmentandcharacterizationofsyntheticglucopyranosyllipidadjuvantsystemasavaccineadjuvant AT martinfriede developmentandcharacterizationofsyntheticglucopyranosyllipidadjuvantsystemasavaccineadjuvant AT thomassvedvick developmentandcharacterizationofsyntheticglucopyranosyllipidadjuvantsystemasavaccineadjuvant AT stevengreed developmentandcharacterizationofsyntheticglucopyranosyllipidadjuvantsystemasavaccineadjuvant |
_version_ |
1716804947487490048 |